Ricardo Sousa's Contact Details

Ricardo Sousa's Company Details

FASTinov SA

Porto, Porto District, Portugal • 12 Employees
Medical Devices

FASTinov SA is an in vitro diagnostic company in the field of ID/AST developing diagnostic tools to combat infectious disease in global healthcare settings. The focus of the FAST line of products is to provide clinicians with information on how to treat life-threatening infections and solutions for the global challenge of antibiotic resistance and hospital acquired infections. The company products are designed to enable the RAPID identification of ICU/acute care patients who are colonized or infected with life-threatening bacteria including multi-drug resistant organisms, MDROs. The company ULTRA-RAPID AST works directly from Positive Blood Cultures and the technology allows the elimination of the lengthy culture and sample preparation steps required prior to testing for antimicrobial susceptibility, with a reduction of time to results from 36-48h to same day results in LESS THAN 2h. FASTinov SA was established in 2013 by clinicians from the University of Porto, Faculty of Medicine together with investment companies Armilar Ventures and Busy Angels and is headquartered in Porto, Portugal. Next Generation AST system! From Positive Blood Cultures to results in 2 hours!The global emergence and spread of antimicrobial resistance is a major medical problem. In case of a severe infection, empiric therapy by GP is immediately started - since diagnostic confirmation, including a susceptibility profile, takes >48h with current technology. In order to support clinical decisions with a fast turnaround time, FASTinov offers a time saving, flow cytometric solution to be directly applied to positive blood cultures of bacteria or fungi. The innovative approach allows the determination of the susceptibility phenotype in a 2 hours vs the +48 hours needed with current standard methods. "FAST"methodology (Flow Cytometry Antimicrobial Susceptibility Test) fills a gap in the AST methods available in the market: microbial cells can be discriminated in terms of susceptible versus re